Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Jean Sebastien FRENEL"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Recently many therapeutic classes have emerged in advanced hormone receptor-positive breast cancer, which is the leading cause of cancer death in women. In absence of visceral crisis, treatment relies on endocrine therapy combined with cyclin depende
Externí odkaz:
https://doaj.org/article/8b1b051acf4145d58d96075668e7bba1
Autor:
Paule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, Carole Gourmelon, Sophie Abadie Lacourtoisie, Dominique Berton Rigaud, Patrick Soulié, Jean Sebastien Frenel, Mario Campone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Endocrine therapy is the mainstay of treatment of estrogen-receptor-positive (ER+) breast cancer with an overall survival benefit. However, some adaptive mechanisms in the tumor emerge leading to the development of a resistance to this therapy. A bet
Externí odkaz:
https://doaj.org/article/ca4c0958e557434eae385369c0c3ecc5
Autor:
Amandine Billaud, Louise-Marie Chevalier, Paule Augereau, Jean-Sebastien Frenel, Christophe Passot, Mario Campone, Alain Morel
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Targeted therapies in oncology are promising but variants of uncertain significance (VUS) limit their use for clinical management and necessitate functional testing in vitro. Using BRCA1 and BRCA2 variants, which have consequences
Externí odkaz:
https://doaj.org/article/79c1e3cddf6545f2a4bd74aab526e620
Autor:
Ke Zhou, Martine Bellanger, Sophie Le Lann, Marie Robert, Jean-Sebastien Frenel, Mario Campone
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposePatient-reported outcomes (PROs) have been widely used to measure breast cancer (BC) treatment outcomes. However, evidence is still limited on using routinely PROs to personalize treatment decision-making, including or not chemotherapy, target
Externí odkaz:
https://doaj.org/article/a8d331394c49474f81479554691a6e46
Autor:
Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi, Anne Patsouris, Josselin Annic, Lounes Djerroudi, Marion Lavigne, Jean-Yves Pierga, Paul Coppo, Francois-Clement Bidard
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing o
Externí odkaz:
https://doaj.org/article/f7239abd3511401b9773a7aef4c9d1ce
Autor:
Mathilde Richard, Jean Sebastien FRENEL, Laurent Mathiot, Mario Campone, Mathilde Colombie, Marie Robert, Anne Patsouris, Frederic Bigot, Julie Gavard, Gwennan André-Grégoire, Laetitia Guevel
Publikováno v:
Cancer Research. 83:P3-11
CONTEXT: Endocrine therapy combined with CDK4/6 inhibitor is the standard frontline treatment for the vast majority of HR+/HER2- metastatic breast cancer (MBC) patients. Despite an overall survival benefit, patients eventually progress and mechanisms
Autor:
Emeline, Colomba, Jérôme, Alexandre, Gwénaël, Le Teuff, Catherine, Genestie, Dahna, Coupez, Isabelle Ray, Coquard, Pierre Emmanuel, Brachet, Sixtine, de Percin, Christophe, Sajous, Michel, Fabbro, Nicolas, Delanoy, Florence, Joly, Jean Sebastien, Frenel, Patricia, Pautier, Alexandra, Leary
Publikováno v:
Gynecologic Oncology. 169:78-84
Around 15% of metastatic endometrial carcinoma (EC) are MMRd/MSI-H improving response to immune checkpoint inhibitors (ICI). So far, few data existed considering the chemotherapy (CT) sensitivity in MMRd/MSI-H EC, especially response to first-line pl
Autor:
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Publikováno v:
The lancet : international edition
Background An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast0
Autor:
Ivan Caramanna, Julie M de Kort, Alba A Brandes, Walter Taal, Michael Platten, Ahmed Idbaih, Jean Sebastien Frenel, Wolfgang Wick, Chandrakanth Jayachandran Preetha, Martin Bendszus, Philipp Vollmuth, Jaap C Reijneveld, Martin Klein
Publikováno v:
Neuro-Oncology Practice, 9(4), 310-316. Oxford University Press
Caramanna, I, de Kort, J M, Brandes, A A, Taal, W, Platten, M, Idbaih, A, Frenel, J S, Wick, W, Preetha, C J, Bendszus, M, Vollmuth, P, Reijneveld, J C & Klein, M 2022, ' Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma : Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 ', Neuro-Oncology Practice, vol. 9, no. 4, pp. 310-316 . https://doi.org/10.1093/nop/npac022
Caramanna, I, de Kort, J M, Brandes, A A, Taal, W, Platten, M, Idbaih, A, Frenel, J S, Wick, W, Preetha, C J, Bendszus, M, Vollmuth, P, Reijneveld, J C & Klein, M 2022, ' Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma : Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 ', Neuro-Oncology Practice, vol. 9, no. 4, pp. 310-316 . https://doi.org/10.1093/nop/npac022
Background In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess
Autor:
Damien Pouessel, Soléakhéna Ken, Valérie Gouaze-Andersson, Lucie Piram, Augustin Mervoyer, Delphine Larrieu-Ciron, Bastien Cabarrou, Amélie Lusque, Marie Robert, Jean-Sebastien Frenel, Emmanuelle Uro-Coste, Pascale Olivier, Muriel Mounier, Umberto Sabatini, Eduardo Hugo Sanchez, Mehdi Zouitine, Ahmad Berjaoui, Elizabeth Cohen-Jonathan Moyal
Publikováno v:
The Oncologist.
Background Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalum